Currently out of the existing stock ratings of Kelly Shi, 64 are a BUY (92.75%), 5 are a HOLD (7.25%).

Kelly Shi

Work Performance Price Targets & Ratings Chart

Analyst Kelly Shi, carries an average stock price target met ratio of 52.06% that have a potential upside of 43.75% achieved within 183 days. Previously, Kelly Shi worked at JEFFERIES.

Kelly Shi’s has documented 137 price targets and ratings displayed on 25 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on GLUE, Monte Rosa Therapeutics at 17-Dec-2025.

Wall Street Analyst Kelly Shi

Analyst best performing recommendations are on IBRX (IMMUNITYBIO).
The best stock recommendation documented was for MLTX (MOONLAKE IMMUNOTHERAPEUTICS) at 9/29/2025. The price target of $8 was fulfilled within 4 days with a profit of $1.75 (28%) receiving and performance score of 70.

Average potential price target upside

of $47.44 (34.4%) on ASND (ASCENDIS PHARMA AS).
of $28.77 (33.05%) on INSM (INSMED).
of $15.83 (192.8%) on COGT (COGENT BIOSCIENCES).

HGEN Humanigen IMGN ImmunoGen KYMR Kymera Therapeutics MLTX MoonLake Immunotherapeutics IBRX Immunitybio ACET Adicet Bio PTCT PTC Therapeutics ADAG Adagene ASND Ascendis Pharma AS CNTA Centessa Pharmaceuticals PLC ADR FHTX Foghorn Therapeutics INCY yte TIL Instil Bio IMAB I-Mab PROK ProKidney Corp. ALDX Aldeyra The INSM Insmed VSTM Verastem BGNE BeiGene Ltd CABA Cabaletta Bio COGT Cogent Biosciences GLUE Monte Rosa Therapeutics HRTX Heron Therapeuti KROS Keros Therapeutics SNDX Syndax Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Tiago Fauth (CREDIT SUISSE)